IGF-1 LR3, IGF-1 DES and MGF: growth-factor peptides and the hypoglycemia problem
Last updated: October 27, 2026 · 9 min read · By the Grey Peptides Editorial Board
- IGF-1 is a growth hormone that also lowers blood sugar, much like insulin. IGF-1 LR3 and IGF-1 DES are engineered or truncated versions that bind far less to the proteins that normally restrain it; MGF is a different, short fragment.
- None of the three has a published human study. The IGF-1 drug approved in the US, mecasermin (Increlex), caused low blood sugar in 42% of children in its trials, including seizures, and must be taken with food.
- Higher natural IGF-1 is linked to higher risk of several cancers, and the approved drug's label reports cancers in treated children. All three peptides are banned in sport, and black-market IGF-1 analogues have been found oxidised.
IGF-1: the hormone behind the peptides
Insulin-like growth factor 1 (IGF-1) mediates many of growth hormone's anabolic actions 1. As its name says, it is also structurally similar to insulin and shares many of insulin's biological properties. In a 1987 study in eight healthy adults, a rapid intravenous injection of recombinant IGF-1 produced a fall in blood glucose nearly identical to insulin's at the doses used, reaching about 2 mmol/L after 30 minutes, although on a molecule-for-molecule basis it was only 6% as potent as insulin at lowering blood sugar; the authors attributed the low blood sugar to the very high levels of free IGF-1 the injection produced 2.
In the blood, IGF-1 is mostly locked up. More than 80% is bound in a complex with IGF-binding protein 3 and another protein 3. That restraint is the key to understanding the research peptides: two of them bind those proteins far less than IGF-1 does 4 5.
Three molecules sold under one idea
Two of the three are altered forms of IGF-1 and the third is a fragment of a related molecule. From our encyclopedia entries, as of October 27, 2026:
| Mecasermin (Increlex) | IGF-1 LR3 | IGF-1 DES | MGF | |
|---|---|---|---|---|
| What it is | Recombinant human IGF-1, identical to the natural hormone | IGF-1 with one substitution and a 13-amino-acid extension | IGF-1 missing its first three amino acids | A 24-amino-acid peptide from the IGF-1Ec splice variant |
| Binding proteins | Normal binding | Much reduced binding | Much reduced binding | Not a full IGF-1 |
| Human studies | Approved after trials in children; registries | None published | None published | None published (human cell and tissue studies only) |
| US status | FDA-approved | Not approved | Not approved | Not approved |
| Evidence grade | High | Low | Low | Low |
| WADA | All prohibited at all times (S2.3, growth factors) | |||
IGF-1 LR3 Low is full-length IGF-1 with one amino acid swapped and a 13-amino-acid extension added at the start 6, an analogue with much reduced affinity for IGF-binding proteins 5. In a rat muscle cell line, added IGF-binding protein 3 still held back the cell growth it stimulated, as it did for IGF-1, but did not hold back the cell maturation it drove 7. A 2023 study produced it in yeast for clinical and scientific research use 8.
IGF-1 DES Low, or des(1-3)IGF-1, is IGF-1 missing its first three amino acids. Unlike LR3, it occurs naturally and has been isolated from bovine colostrum, human brain and pig uterus. Losing the glutamate at position 3 sharply reduces binding to IGF-binding proteins, which makes it about ten times as potent as IGF-1 at stimulating cultured cells; a 1996 review noted that its clinical uses had not been evaluated 4.
MGF Low, mechano growth factor, is not an IGF-1 at all in the form sold. The IGF-1 gene can be read in several ways, and one variant, IGF-1Ec, is increased in skeletal muscle after injury, in heart muscle after a heart attack and in cancer tissue; the peptide studied as MGF is a synthetic copy of the last 24 amino acids of that variant's end piece 9. Our IGF-1 LR3 vs MGF comparison covers those two side by side.
What the research actually shows
None of the three has a published study in people. IGF-1 LR3's studies are in animals: infused for a week in guinea pigs it enlarged the adrenals, gut, kidneys and spleen but did not change body weight gain or carcass composition 5; injected under the skin of newborn calves it lowered blood glucose and insulin, while given by mouth it had no effect 10; in rats it increased absorption of a glucose analogue from the gut, which the authors put down to a larger gut lining 11; and in fetal sheep a short infusion lowered fetal insulin by 66% during a glucose clamp 12. IGF-1 DES's selective effects in animals were most evident in gut tissue 4. MGF's evidence is cultured human muscle cells, in which it extended the growth of satellite cells from newborn and young adult but not old donors 13.
Not one of these studies tested muscle growth in healthy adult humans, which is what the products are sold for. The animal results that do exist point as much to effects on glucose and insulin as to growth.
The hypoglycemia problem
The clearest guide to what IGF-1 does in people comes from the one approved form. Mecasermin, sold as Increlex, is recombinant human IGF-1, approved for growth failure in children aged 2 and older with severe primary IGF-1 deficiency or growth hormone gene deletion with neutralising antibodies 3. Its label's first warning is hypoglycaemia: severe low blood sugar leading to seizures has been observed, and because mecasermin has insulin-like effects it must be given within 20 minutes before or after a meal or snack, with glucose monitoring while the dose is adjusted 3.
The numbers are striking. In clinical studies of 71 children treated for an average of 3.9 years, 30 (42%) had hypoglycaemia at least once; most episodes were mild or moderate, but five children had severe episodes needing help and four had seizures or loss of consciousness. Fourteen of the 30 had had hypoglycaemia before treatment, and episodes were most frequent in the first month 3. A later analysis of a European registry of 306 treated children found about 0.11 hypoglycaemia events per patient per treatment year (0.01 serious), more often in children with earlier hypoglycaemia or Laron syndrome; three of its ten authors worked for the drug company Ipsen 14. That is in children with a genuine deficiency, under specialist supervision, using a product made to pharmaceutical standards with a known dose.
The research analogues raise the stakes. IGF-1 LR3 and IGF-1 DES bind far less to the binding proteins that normally buffer IGF-1 5 4, and DES is about ten times as potent as IGF-1 in cultured cells 4. In calves, injected IGF-1 LR3 lowered blood glucose and insulin 10. We found no study measuring how much they lower blood sugar in people, how long the effect lasts, or how it interacts with exercise, fasting, alcohol or diabetes medicines. The approved drug's trials show where low blood sugar can lead: seizures and loss of consciousness 3.
The cancer question
IGF-1 promotes cell growth and survival, which is why its link with cancer has been studied for decades. In UK Biobank, among 394,388 people without cancer at the start, higher blood IGF-1 was associated with higher risks of colorectal, breast, prostate and thyroid cancer, and with lower risks of ovarian and liver cancer, over about seven years; the authors noted that reverse causation could not be excluded 15. Those are associations with the body's own IGF-1 levels, not a measure of what a growth-factor injection does.
The approved drug's label is more direct. It reports postmarketing cases of malignant neoplasms in children treated with mecasermin, a variety of cancers, mostly in children with rare genetic conditions or other conditions that already carry increased cancer risk, and more often in children given higher than recommended doses; it says it is unknown whether the treatment is related, and therapy should be stopped if cancer develops 3. For MGF, tissue studies found its gene variant more highly expressed in colorectal cancers and high-grade polyps than in normal colon 16. None of this proves the research peptides cause cancer, and none of them has been studied for it in people.
Other risks on the approved label
Mecasermin's label lists further warnings that show what IGF-1 can do: severe allergic reactions including anaphylaxis, raised pressure inside the skull, enlarged tonsils and adenoids, slipped growth plates in the hip, worsening scoliosis, and, because of a benzyl alcohol preservative, a warning against use in infants 3. Its trials also reported ear problems, headache and joint pain among common side effects 3. These are effects of IGF-1 at controlled doses in children; adults injecting more potent analogues have no comparable safety information at all.
What is actually in the vial
Product quality is a separate problem. Researchers developing a doping test for IGF-1 analogues found oxidised, lower-quality peptide in black-market products 17. Anti-doping laboratories can now detect LongR3-IGF-1, R3-IGF-1 and DES(1-3)IGF-1 in plasma at low concentrations 18, reflecting long-standing interest in IGF-1 as an alternative to growth hormone among athletes, for whom IGF-1 compounds have been advertised online and on the black market for years 1. All of these are prohibited at all times under WADA's growth factors section 6.
Do they build muscle?
We found no published study testing these products in people, so there is no evidence either way. IGF-1 mediates many of growth hormone's anabolic actions, which is why it attracts athletes 1, but the guinea pig study of IGF-1 LR3 found no change in carcass composition after a week 5, and the animal studies that report effects mostly concern the gut, glucose and insulin. Black-market IGF-1 analogues have also been found oxidised 17.
The bottom line
As of October 27, 2026, IGF-1 LR3, IGF-1 DES and MGF have animal and cell data and no published human studies. Two bind the proteins that restrain IGF-1 far less than the hormone itself, and the approved form of that hormone caused low blood sugar in four in ten treated children in its trials and carries a seizure warning. Higher IGF-1 is associated with several cancers. If you are considering any of them, the questions are what is in the vial, what it will do to your blood sugar, and why you would take that risk on no human evidence. Nothing here is advice or a dose.
Frequently asked questions
What are the side effects of IGF-1 LR3?
No human study has measured them. IGF-1 lowers blood sugar like insulin, and the only approved IGF-1 caused hypoglycaemia in 42% of children in its trials, including seizures. IGF-1 LR3 binds far less to the proteins that normally restrain IGF-1.
What is the difference between IGF-1 LR3 and IGF-1 DES?
LR3 is IGF-1 with a substitution and a 13-amino-acid extension; DES is IGF-1 missing its first three amino acids and has been isolated from natural sources. Both bind IGF-binding proteins poorly; DES is about ten times as potent as IGF-1 in cultured cells.
Is MGF the same as IGF-1?
No. The peptide studied as MGF is a synthetic copy of the last 24 amino acids of the IGF-1Ec splice variant, not the full IGF-1 hormone.
Is there an approved IGF-1?
Yes. Mecasermin (Increlex) is approved in the US for children aged 2 and older with severe primary IGF-1 deficiency, with warnings for hypoglycaemia, allergic reactions and other effects.
Related on Grey Peptides
Sources
- Guha, N., et al. (2013). Insulin-like growth factor-I (IGF-I) misuse in athletes and potential methods for detection. Anal Bioanal Chem, 405(30), 9669-83. PMID: 23934394
- Guler, H. P., et al. (1987). Short-term metabolic effects of recombinant human insulin-like growth factor I in healthy adults. N Engl J Med, 317(3), 137-40. PMID: 3299085
- Eton Pharmaceuticals. Increlex (mecasermin) US prescribing information, sections 1, 2, 5, 6.1 and 12.3 (DailyMed set d5b2b0e1, version 5, effective May 18, 2026; confirmed current on DailyMed October 27, 2026). DailyMed
- Ballard, F. J., et al. (1996). Des(1-3)IGF-I: a truncated form of insulin-like growth factor-I. Int J Biochem Cell Biol, 28(10), 1085-7. PMID: 8930132
- Conlon, M. A., et al. (1995). Long R3 insulin-like growth factor-I (IGF-I) infusion stimulates organ growth but reduces plasma IGF-I, IGF-II and IGF binding protein concentrations in the guinea pig. J Endocrinol, 146(2), 247-53. PMID: 7561636
- Grey Peptides encyclopedia entries for IGF-1 LR3, IGF-1 DES, MGF and mecasermin: IGF-1 LR3 sequence; WADA 2026 and 2027 status S2.3. Read October 27, 2026.
- Xi, G., et al. (2004). Effect of recombinant porcine IGFBP-3 on IGF-I and long-R3-IGF-I-stimulated proliferation and differentiation of L6 myogenic cells. J Cell Physiol, 200(3), 387-94. PMID: 15254966
- Lu, Z., et al. (2023). Recombinant expression of IGF-1 and LR3 IGF-1 fused with xylanase in Pichia pastoris. Appl Microbiol Biotechnol, 107(14), 4543-4551. PMID: 37261455
- Vassilakos, G., et al. (2014). Biological activity of the e domain of the IGF-1Ec as addressed by synthetic peptides. Hormones (Athens), 13(2), 182-96. PMID: 24776619
- Hammon, H., et al. (1998). Endocrine and metabolic changes in neonatal calves in response to growth hormone and long-R3-insulin-like growth factor-I administration. Biol Neonate, 73(2), 121-8. PMID: 9483305
- Garnaut, S. M., et al. (2002). Effects of insulin-like growth factor-I and its analogue, long-R3-IGF-I, on intestinal absorption of 3-O-methyl-D-glucose are less pronounced than gut mucosal growth responses. Growth Factors, 20(1), 17-25. PMID: 11999215
- White, A., et al. (2023). Attenuated glucose-stimulated insulin secretion during an acute IGF-1 LR3 infusion into fetal sheep does not persist in isolated islets. J Dev Orig Health Dis, 14(3), 353-361. PMID: 37114757
- Kandalla, P. K., et al. (2011). Mechano Growth Factor E peptide (MGF-E), derived from an isoform of IGF-1, activates human muscle progenitor cells and induces an increase in their fusion potential at different ages. Mech Ageing Dev, 132(4), 154-62. PMID: 21354439
- Bang, P., et al. (2023). Frequency and Predictive Factors of Hypoglycemia in Patients Treated With rhIGF-1: Data From the Eu-IGFD Registry. J Clin Endocrinol Metab, 109(1), 46-56. PMID: 37579214
- Knuppel, A., et al. (2020). Circulating Insulin-like Growth Factor-I Concentrations and Risk of 30 Cancers: Prospective Analyses in UK Biobank. Cancer Res, 80(18), 4014-4021. PMID: 32709735
- Alagaratnam, S., et al. (2020). Increased expression of IGF-1Ec with increasing colonic polyp dysplasia and colorectal cancer. J Cancer Res Clin Oncol, 146(11), 2861-2870. PMID: 32772171
- Mongongu, C., et al. (2021). Detection of LongR(3) -IGF-I, Des(1-3)-IGF-I, and R(3) -IGF-I using immunopurification and high resolution mass spectrometry for antidoping purposes. Drug Test Anal, 13(7), 1256-1269. PMID: 33587816
- Thomas, A., et al. (2017). Determination of LongR(3)-IGF-I, R(3)-IGF-I, Des1-3 IGF-I and their metabolites in human plasma samples by means of LC-MS. Growth Horm IGF Res, 35, 33-39. PMID: 28668757
Educational information, not medical advice. Each dose in this guide names its source, an approved label or a published study. None is a recommendation for you. An unapproved compound has no established safe or effective human dose, and products sold for “research use only” are not made or tested for people. Talk to a doctor before acting on anything on this site, including before you start, stop or change any medicine or dose.
New guides and rule changes, by email
One short email when a peptide's legal status moves — an FDA or PCAC decision, a WADA list change, an enforcement action — plus new guides and tools. At most one a week, and none when nothing changes. The newsletter has not started sending yet: your first email will be its first issue.
We keep your email address and the page you signed up from, nothing else. How it works · Privacy · RSS instead